LogicGate Named Winner of the ISACA Innovative Solutions Award for the Organization's AI Governance Solution

The industry-recognized solution helps enterprises better govern and manage the implementation and usage of AI technology throughout the entirety of their organizations.
CHICAGO, May 23, 2025 /PRNewswire/ -- LogicGate, the modern, enterprise-grade provider of governance, risk, and compliance (GRC) solutions, today announced its AI Governance Solution was recognized for the prestigious ISACA Innovative Solutions Award. The industry accolade honors LogicGate for its groundbreaking AI Governance Solution, designed to empower safe innovation, accelerate business growth, and enable organizations to navigate the complexities of artificial intelligence responsibly.
The ISACA Innovative Solutions Award acknowledges individuals or organizations that have developed or utilized technology to solve significant business or societal challenges. Judging criteria include the innovative use or development of new technology, promotion of ISACA's core domains, impact and global reach of the solution, and the quality of the nomination.
'LogicGate's AI Governance Solution is not just another tool in the GRC space—it is essential to reshaping how organizations approach AI governance,' said Matt Kunkel, Co-Founder and CEO at LogicGate. 'With the rapid evolution and widespread adoption of AI, particularly generative AI, every industry is confronted with the challenge of governing the use of this technology and its various applications. Our approach was to create a prescriptive yet flexible AI governance framework that enterprises could easily adopt and tailor to their unique AI guidelines and requirements.'
As AI technologies become increasingly integral to business operations, the necessity for robust AI governance has become paramount. Recent research by OCEG on the 'Use of AI for GRC' found that while 82% of respondents agree or strongly agree they must adopt generative AI, only 12% reported having a documented AI Governance plan in place. This highlights a critical gap that LogicGate's AI Governance Solution aims to address.
LogicGate's AI Governance Solution provides a comprehensive set of workflows to ensure AI initiatives are transparent, accountable, and aligned with regulatory standards. The solution includes centralized use case management, cyber risk assessments, policy management, controls compliance, and third-party AI risk oversight, all within an easy-to-use platform. This holistic approach bridges the growing gap between GRC and AI, enabling organizations to confidently harness the power of AI while safeguarding against unintended consequences.
'A key differentiator of LogicGate's AI Governance Solution is its integration with the full spectrum of governance, risk, compliance, and cybersecurity programs,' said Jon Siegler, Co-Founder and Chief Product Officer at LogicGate. 'This integration ensures that AI governance processes are seamlessly incorporated into cyber risk management, third-party risk management, policy management, and controls management.'
Specifically, LogicGate's AI Governance Solution enables organizations to:
LogicGate, along with other award recipients of the 2025 Global Achievement Awards, Chapter Awards, Certification Exam Top Scores, and the 2025 class of the Hall of Fame were recognized at the ISACA Awards Celebration in Orlando, Florida, during ISACA's 2025 North America Conference. To view the full list of award recipients, visit www.isaca.org/awards.
About LogicGate
LogicGate® is a global, market-leading SaaS company empowering customers to effectively manage and scale their cyber risk and control, third-party risk management, controls compliance, enterprise risk, and operational resilience programs. Recognized as one of four leading global GRC platforms, Risk Cloud® is built with usability in mind, including a no-code interface and graph-database management making the technology flexible, agile and scalable to support various levels of GRC maturity and bolster business outcomes. With an unwavering commitment to fostering business resilience in dynamic landscapes, LogicGate empowers customers to quantify risk, strengthen their security posture, and have visibility into information to create strategic advantages and support business objectives. Learn more about LogicGate's solutions by visiting www.logicgate.com or LinkedIn.
View original content to download multimedia: https://www.prnewswire.com/news-releases/logicgate-named-winner-of-the-isaca-innovative-solutions-award-for-the-organizations-ai-governance-solution-302463526.html
SOURCE LogicGate

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

傳蘋果將捨棄Google合作 將收購AI搜尋黑馬Perplexity

科技中心／李宜樺報導 ▼▲蘋果傳新併購消息！恐捨棄Google，轉密會AI搜尋新星Perplexity。（圖／翻攝自YT@Apple） AI戰升溫，科技巨頭火力全開！繼Meta投資Scale AI後，如今傳出蘋果也悄悄布局，要收購AI搜尋新貴「Perplexity AI」，甚至傳出考慮放棄Google作為預設搜尋引擎。這場看似平靜的搜尋戰場，已悄然掀起風暴！ 根據《彭博》知名科技記者Mark Gurman爆料，蘋果併購部門主管Adrian Perica已在內部討論是否收購Perplexity，雖仍處於早期階段，但若交易成真，將是蘋果史上最大規模併購案──該公司估值高達140億美元，遠超2014年30億美元收購Beats的紀錄。 除了併購，蘋果也考慮另一合作模式，將Perplexity整合至Safari與Siri，作為替代Google搜尋的AI解決方案。畢竟蘋果與Google的搜尋合作協議，正面臨美國反壟斷調查威脅，恐有被迫拆夥的可能。 Perplexity成立僅兩年，卻以AI驅動搜尋技術嶄露頭角，透過自動總結、引文標示等功能挑戰Google霸主地位，甚至已與三星展開深度合作，成為蘋果收購計畫的潛在障礙。 Perplexity對收購傳聞低調回應，稱「目前沒有相關消息」，但該公司近期與多家科技巨頭接觸頻繁，包括Meta也曾試圖收購、並挖角其CEO Aravind Srinivas，顯示AI搜尋市場人才爭奪戰已進入白熱化。 當AI搜尋成為下一代搜尋引擎的競爭主戰場，蘋果此舉無疑是對Google發出重大威脅。科技巨頭的版圖重組已開始，誰能掌握搜尋流量與AI技術，誰就能主宰未來。 更多三立新聞網報導2025報稅必知／報稅倒數9天 你真的報完了嗎？「這一步」沒做＝白報！美軍參戰 介入以伊戰爭！衝突升級 冷靜異常的黃金現補漲行情？全球熱錢瘋搶亞洲 高盛曝對沖基金5年最大買盤新光金、新壽5月再虧破百億 靠準備金撐盤仍難止血？

Yahoo

an hour ago

• Yahoo

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory Verdine. The parties intend to execute a definitive agreement shortly. Under the collaboration, XtalPi will leverage its end-to-end, AI and robotics-driven platform to discover and develop small molecule and antibody drug candidates for multiple DoveTree-selected targets addressing oncology, autoimmune disorders, and neurological diseases. Pursuant to the LOI, XtalPi will receive an upfront payment of $51 million within 10 days of executing the definitive agreement and an additional $49 million within 180 days. Subject to final agreement terms, XtalPi is also eligible to receive potential development and commercial milestone payments exceeding $10 billion, as well as tiered, single-digit royalties on annual net product sales. DoveTree will obtain exclusive global development and commercialization rights to the resulting therapeutics. Professor Gregory Verdine, the Erving Professor of Chemistry at Harvard University, is a pioneer in chemical biology and a distinguished serial entrepreneur. Appointed to Harvard's faculty at age 29, he became the Chemistry Department's youngest tenured professor in nearly five decades at 35. He has elucidated the molecular mechanism of epigenetic DNA methylation and revealed the pathways by which certain genotoxic forms of DNA damage are identified and eradicated. He is a leading figure in the field of new therapeutic modalities, and has developed of a new class of therapeutics termed stapled peptides, enabling drug development against targets long considered undruggable. As an entrepreneurial leader, Professor Verdine has founded or co-founded over ten biotechnology companies, including five publicly listed entities: Enanta Pharmaceuticals (NASDAQ: ENTA), Tokai Pharmaceuticals (NASDAQ: TKAI), and Wave Life Sciences (NASDAQ: WVE), among others. One venture was acquired by a major pharmaceutical company, while others continue developing disruptive medicines with a special focus on oncology. Three therapeutics he spearheaded—romidepsin (Istodax®), paritaprevir (a component of Viekira Pak®), and glecaprevir (a component of Mavyret®) —have received FDA approval. Professor Verdine currently serves as a Venture Partner at Andreessen Horowitz (a16z), a role he previously held at Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures. He was also a Special Advisor to Texas Pacific Group. His advisory engagements include top research institutions such as the U.S. National Cancer Institute and Harvard Medical School. "By integrating XtalPi's cutting-edge AI capabilities with decades of drug development expertise, we have a unique opportunity to deliver transformative therapies to patients worldwide," stated Professor Verdine. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc.

Yahoo

an hour ago

• Yahoo

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory Verdine. The parties intend to execute a definitive agreement shortly. Under the collaboration, XtalPi will leverage its end-to-end, AI and robotics-driven platform to discover and develop small molecule and antibody drug candidates for multiple DoveTree-selected targets addressing oncology, autoimmune disorders, and neurological diseases. Pursuant to the LOI, XtalPi will receive an upfront payment of $51 million within 10 days of executing the definitive agreement and an additional $49 million within 180 days. Subject to final agreement terms, XtalPi is also eligible to receive potential development and commercial milestone payments exceeding $10 billion, as well as tiered, single-digit royalties on annual net product sales. DoveTree will obtain exclusive global development and commercialization rights to the resulting therapeutics. Professor Gregory Verdine, the Erving Professor of Chemistry at Harvard University, is a pioneer in chemical biology and a distinguished serial entrepreneur. Appointed to Harvard's faculty at age 29, he became the Chemistry Department's youngest tenured professor in nearly five decades at 35. He has elucidated the molecular mechanism of epigenetic DNA methylation and revealed the pathways by which certain genotoxic forms of DNA damage are identified and eradicated. He is a leading figure in the field of new therapeutic modalities, and has developed of a new class of therapeutics termed stapled peptides, enabling drug development against targets long considered undruggable. As an entrepreneurial leader, Professor Verdine has founded or co-founded over ten biotechnology companies, including five publicly listed entities: Enanta Pharmaceuticals (NASDAQ: ENTA), Tokai Pharmaceuticals (NASDAQ: TKAI), and Wave Life Sciences (NASDAQ: WVE), among others. One venture was acquired by a major pharmaceutical company, while others continue developing disruptive medicines with a special focus on oncology. Three therapeutics he spearheaded—romidepsin (Istodax®), paritaprevir (a component of Viekira Pak®), and glecaprevir (a component of Mavyret®) —have received FDA approval. Professor Verdine currently serves as a Venture Partner at Andreessen Horowitz (a16z), a role he previously held at Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures. He was also a Special Advisor to Texas Pacific Group. His advisory engagements include top research institutions such as the U.S. National Cancer Institute and Harvard Medical School. "By integrating XtalPi's cutting-edge AI capabilities with decades of drug development expertise, we have a unique opportunity to deliver transformative therapies to patients worldwide," stated Professor Verdine. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data